UF Health Cancer Center researchers will present a wide range of innovative cancer research at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 31 to June 4 in Chicago.
The ASCO Annual Meeting is one of the most significant gathering of oncology professionals worldwide, allowing attendees to make connections and forging collaborations that can change the landscape of cancer care.
The meeting features state-of-the-art research, groundbreaking treatments and visionary insights. This year’s program features over 200 sessions complementing Dr. Lynn Schuchter’s Presidential theme “The Art and Science of Cancer Care: From Comfort to Cure.”
UF Health Cancer Center members appear in bold below.
Oral Abstracts
June 3 | 9:45-11:15 a.m.
Julia Close, M.D.
Chair: Medical Education and Professional Development track; Rapid Oral Abstract Session
June 2 | 8-11 a.m.
A pilot study of post-consolidation chemoimmunotherapy for high-risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group.
Ami Desai, Arlene Naranjo, Brian LaBarre, Kelly Goldsmith, Meaghan Granger, Lisa States, Sean Green, Mariel Trunzo, Wendy Fitzgerald, Steven DuBois, Rochelle Bagatell, Julie Park, Araz Marachelian
RMS13: A phase II trial using risk adapted focal proton beam radiation and/or surgery with the addition of maintenance chemotherapy in intermediate risk rhabdomyosarcoma.
Jessica Gartrell, Alberto Pappo, Yimei Li, Tushar Patni, Daniel Indelicato, Sara Federico, Elizabeth Stewart, Christopher Tinkle, Sara Helmig, John Lucas, Michael Bishop, Mary McCarville, Karen Albritton, Matthew Krasin
Phase IB study of tovorafenib for children with relapsed/recurrent low-grade gliomas and other MAPK pathway activated tumors.
Karen Wright, Cassie Kline, Mohamed Abdelbaki, Elias Sayour, David Ebb, Matthew Miller, Erin Crotty, Ashley Margol, Lindsay Kilburn, Kenneth Cohen, Anne Bendel, Jennifer Elster, Lianne Greenspan, Pei-Chi Kao, Clement Ma, Wendy London, Michael Prados, Daphne Haas-Kogan, Sabine Mueller
Impact of an objective scoring system on initiation of therapy in patients with International Neuroblastoma Risk Group Staging System (INRGSS) stage MS neuroblastoma: A report from the Children’s Oncology Group.
Leonora Slatnick, Navin Pinto, Arlene Naranjo, Jed Nuchtern, Edward Attiyeh, Rochelle Bagatell, Clare Twist, Meredith Irwin, Steven DuBois, John Maris, Mary Schmidt, Araz Marachelian, Michael Armstrong, Peter Zage, Christopher Weldon, Julie Park, Holly Meany
June 2 | 4:30-6 p.m.
Interpretable artificial intelligence-based analysis for morphologic classification of neuroblastic tumors.
Siddhi Ramesh, Monica Pomaville, Kristina Doytcheva, James Dolezal, Sara Kochanny, Rachel TerHaar, Jacob Brewer, Benjamin Kusswurm, Hiroyuki Shimada, Arlene Naranjo, Peter Pytel, Susan Cohn, Rani George, Alexander Pearson, Mark Applebaum
June 3 | 8:30-9 a.m.
ReNeu: A pivotal phase 2b trial of mirdametinib in children and adults with neurofibromatosis type 1 (NF1)-associated symptomatic inoperable plexiform neurofibroma (PN).
Christopher Moertel, Angela Hirbe, Hans Shuhaiber, David Viskochil, Alpa Sidhu, Kevin Bielamowicz, Michael Weber, Jack Li, L. Smith, Lauren Weintraub, Rene McNall-Knapp, Fouad Hajjar, Nicholas Foreman, Timothy Gershon, Dusica Babovic-Vuksanovic
June 3 | 11:30 a.m.-2:30 p.m.
Comparison of immunoglobulin high-throughput sequencing MRD in bone marrow and peripheral blood in pediatric B-ALL: A report from the Children’s Oncology Group AALL1731.
Rachel Rau, Sumit Gupta, John Kairalla, Cindy Wang, Lik Lee, Heidi Simmons, Karen Rabin, Anne Angiolillo, Mary Shago, Andrew Carroll, Brent Wood, Michael Borowitz, Yvonne Moyer, Alexis Cameron, Christian Deardorff, Tyler Jones, Allison Jacob, Ilan Kirsch, Elizabeth Raetz, Mignon Loh
June 3 | 9:45-11:15 a.m.
A multicenter analysis evaluating educational resources utilized by hematology/oncology fellows (HOF).
Ronak Mistry, Inas Abuali, Karine Tawagi, Daniel Hausrath, Samantha Armstrong, Victoria Chung, Madeline Fitzpatrick, Kyle Kidwell, Ankoor Biswas, Fadi Taza, Maya Abdallah, Moriah Forster, Ahmad Nassar, Shivang Danak (UF Hematology/Oncology Fellow), Vivek Patel
Clinical Science Symposium
June 1 | 1:15-2:45 p.m.
International medical graduates (IMG) representation at international oncology conference meetings.
Arya Mariam Roy, Ziad Bakouny, Nazli Dizman, Zeynep Irem Ozay, Bhavesh Mohan Lal, Rashad Nawfal, Marc Eid, Razane El Hajj Chehade, Marc Machaalani, Ayesha Butt, Charu Aggarwal, Tanios Bekaii-Saab, Mariana Chavez-MacGregor, Gilberto Lopes, Ariela Marshall, Martina Murphy, Taofeek Owonikoko, Alfred Lee, Toni Choueiri
Poster Sessions
JUNE 1 | 1:30-4:30 p.m.
Presenter: Raymond Mailhot Vega
Evaluating scholastic achievement in pediatric brain tumor survivors compared to healthy controls.
Raymond Mailhot Vega, Daniel Indelicato, Julie Bradley, Adeel Markatia, Erin Mobley, Eric Sandler, Philipp Aldana, Jasmin Gomez, Daniel Velasco, Christopher Morris, Amy Crisp, Nancy Mendenhall, M. David Miller
JUNE 1 | 1:30-4:30 P.M.
Presenter: Bently Doonan
Novel RNA-nanoparticle vaccine for the treatment of early melanoma recurrence following adjuvant anti-PD-1 antibody therapy.
Bently Doonan, Christiana Shaw, Ji-Hyun Lee, Eugenio Simon Manso, Hector Mendez-Gomez, Christina Von Roemeling, Duane Mitchell, Elias Sayour, Thomas George
June 3 | 1:30-4:30 p.m.
Presenter: Martina Murphy
Educating hematology-oncology fellows about how to communicate with patients about cancer clinical trials: A needs assessment.
Martina Murphy, Naomi Parker, Tithi Amin, Susan Eggly, Daphne Friedman, Maria Sae-Hau, Andrea Sitlinger, Stephanie Staras, Leah Szumita, Elisa Weiss, Easton Wollney, Kevin Wright, Carma Bylund
June 1 | 9 a.m.-12 p.m.
AMPLIFY-7P, a first-in-human safety and efficacy trial of adjuvant mKRAS-specific lymph node targeted amphiphile ELI-002 7P vaccine in patients with minimal residual disease–positive pancreatic and colorectal cancer.
Craig Devoe, Shubham Pant, Zev Wainberg, Vincent Chung, Thomas George, Pashtoon Kasi, Haley VanWyk, Amy Tavares, James Perry, Thian Kheoh, Lisa McNeil, Esther Welkowsky, Peter DeMuth, Christopher Haqq, Eileen O’Reilly
A phase 2 clinical trial of first-in-class fascin inhibitor NP-G2-044 as monotherapy and in combination therapy with anti-PD-1 immunotherapy in patients with advanced solid tumor malignancies.
Frank Tsai, Michael Birrer, Jason Brown, Sanjay Chandrasekaran, Vincent Chung, Richard Frank, Edward Garmey, Shirish Gadgeel, Thomas George, Shadia Jalal, Andrew Poklepovic, Jennifer Segar, Alexander Spira, Jue Jillian Zhang, Anup Kasi
June 1 | 1:30-4:30 p.m.
Alliance A022101/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer—Evaluating radiation, ablation, and surgery (ERASur).
Eric Miller, Kathryn Hitchcock, Qian Shi, Jesse Dixon, Sepideh Gholami, Sarah White, Christina Wu, Christopher Goulet, Kyung-Wook Jee, Chadwick Wright, Rona Yaeger, Ardaman Shergill, Theodore Hong, Thomas George, Eileen O’Reilly, Jeffrey Meyerhardt, Paul Romesser
Randomized study to assess colonic microbiome changes in response to energy drink consumption (ROSANNA trial).
Tim Jang, Doga Kahramangil, Ji-Hyun Lee, George Kim, Sherise Rogers, Ilyas Sahin, Brian Ramnaraign, Krista Terracina, Johan Nordenstam, Thomas Read, Ryan Thomas, Ye Yang, Christian Jobin, Thomas George
NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC).
Caio Max Rocha Lima, Greg Yothers, Shannon Puhalla, Hanna Sanoff, Deirdre Cohen, Katherine Guthrie, Norah Henry, Patricia Ganz, Scott Kopetz, Peter Lucas, Charles Blanke, Samuel Jacobs, Theodore Hong, Norman Wolmark, Howard Hochster, Thomas George, Michael Overman
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008.
Arvind Dasari, Guan Yu, Scott Kopetz, Shannon Puhalla, Peter Lucas, Ibrahim Halil Sahin, Dustin Deming, Philip Philip, Theodore Hong, Yesenia Rojas-Khalil, Jonathan Loree, Norman Wolmark, Greg Yothers, Thomas George, Christopher Lieu
June 2 | 9 a.m. – 12 p.m.
Leukocyte immunoglobulin-like receptor (LILRB2)-targeted JTX-8064 plus the anti-PD1 inhibitor JTX-4014 (pimivalimab) in immune-checkpoint inhibitor (ICl) pretreated patients (pts) with advanced or metastatic renal cell cancer (mRCC): Results from the multi-stage phase 1-2 INNATE trial.
Primo Lara, Stew Kroll, Jonathan Chatzkel, Deanna Teoh, Vincent Ma, Deepak Kilari, Clara Hwang, Randy Sweis, Kiran Yalamanchili, Julio Peguero, Tianhong Li, Mamta Parikh
June 3 | 1:30-4:30 p.m.
Formation and evaluation of the ASCO medical education community of practice (Med Ed CoP).
Sam Brondfield, Rami Manochakian, Katherine Walsh, Maria Baggstrom, Elizabeth Henry, Aparna Parikh, Deepa Rangachari, Maura Barry, Jennifer Gao, Meredith Giuliani, Annie Im, Kristen Marrone, Mairead McNamara, Martina Murphy, Lori Rosenstein, Brian Russell, Jennifer Tseng, Jennifer Schwartz
Trends in human papilloma virus vaccination uptake by sex and race/ethnicity among US adolescents and young adults, 2011-2020.
Jacqueline Nguyen (UF resident), Arthur Hong, Allan Zhang, Danh Nguyen
Education Sessions
June 1 | 7:35 a.m.
Merry Jennifer Markham, M.D., FACP, FASCO
Presentation: Maintaining Personal Wellness and Resiliency As a Leader
Oncology Division Chiefs and Department Chairs’ Breakfast; Medical Education and Professional Development track
JUNE 2 | 8:10 A.M.
Martina Murphy, M.D.
Presentation: Protecting Versus Preparing Fellows for the “Real World”
Training Program Directors’ Breakfast; Medical Education and Professional Development track
Case-Based Panel
June 2 | 4:30 p.m.
Martina Murphy, M.D.
Moderator and Chair: Harnessing Artificial Intelligence to Enhance Patient–Physician Relationships
Medical Education and Professional Development track
Publication Only
Clinical validation of Northstar response: A novel methylated ctDNA therapy response monitoring assay in patients with advanced gastrointestinal cancers.
Ilyas Sahin, Doga Kahramangil, George Kim, Sherise Rogers, Brian Ramnaraign, Pravalika Manda, Matthew Varga, Gary Palmer, Patrick Ye, Thomas George
Evaluation of a web-based, interactive guide to enhance patient-clinician electronic communication.
Jordan Alpert, Tithi Amin, Zhongyue Zhang, Merry Jennifer Markham, Martina Murphy, Carma Bylund
Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin as a first line treatment for the management of metastatic pancreatic adenocarcinoma: A budget impact analysis from a U.S. payer perspective.
George Kim, Theo Holland, Caity Patrick, Megan Lewis, Paul Cockrum, Alexandra Eddy
HRQoL in patients with GBM: The impact of tumor treating fields.
Drashti Patel, Rajvi Thakkar, Chance Fleeting, Ashley Ghiaseddin
Psychoneurological symptoms, inflammatory biomarkers and gut microbiome richness and diversity in individuals receiving hematopoietic cell transplantation (HCT).
Elham Samami, Angela Starkweather, Debra Lyon, Debra Lynch Kelly, Michael T. Weaver
Clinical large language model to predict loss to follow up for oncology patients discharged to skilled nursing facilities.
Tianshi Liu, Ziyi Chen, Yonghui Wu, Yi Guo, Jonathan Chatzkel, Jiang Bian
Increase in blood pressure in patients with metastatic kidney cancer treated with combination checkpoint inhibitor and vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy.
Rick Lin, Neil Patel, Jonathan Chatzkel, Tarik Benidir, Padraic O’Malley, Paul Crispen, Brian Ramnaraign
Unraveling the role of CTLA-4 variants in acute kidney injury after ICI treatments.
Yanfei Wang, Chenxi Xiong, Jiang Bian, Qianqian Song, Jing Su
First-line treatment patterns among patients with metastatic pancreatic ductal adenocarcinoma in the real-world setting.
Syvart Dennen, Joanna Harton, Paul Cockrum, George Kim, Joanna MacEwan
Racial/ethnic distribution of participants in NRG oncology clinical trials: 2014-2023.
James Dignam, Paul Romitti, Sue Yom, Felix Feng, Jeffrey Bradley, Minesh Mehta, Deborah Bruner, Jennifer Wenzel, Eleftherios Mamounas, Thomas George, Theodore Hong, Carol Aghajanian, Maria Werner-Wasik, Alexandra Thomas
The survival benefits and the risk of severe renal injury of immune checkpoint inhibitors in patients with cancer: The real-world evidence from the National Clinical Cohort Collaborative (N3C).
Yao Chen, Xiaochun Li, Vithal Madhira, Tyler Shugg, Shadia Jalal, Michael Eadon, Benjamin Bates, Noha Sharafeldin, Umit Topaloglu, Qianqian Song, Jing Su
Black/African American participation in cancer clinical trials: A qualitative study of community members, patients with cancer, and survivors (Detroit, MI) using CBPR.
Sylvester Antwi, Linda Kaljee, Doreen Dankerlui, Eleanor Walker, Harriet Larrious-Lartey, Barbara Brush, Barbara Israel, Donna Harris, Sophia Chue, Nayomi Cawthome, Cassandra Mills, Valerie Ofori Aboah, Gwendolyn Daniels, Livingstone Aduse-Poku, Chris Coombe, Zachary Rowe, La’Toshia Patman, Wayne Ramocan, Denise White Perkins, Evelyn Jiagge
Clinicopathologic and treatment characteristics of mixed hepatocellular carcinoma-intrahepatic cholangiocarcinoma (HCC-ICC).
Muhammet Ozer, Suleyman Goksu, Ilyas Sahin
